Dermatitis Global Market Report 2024

The dermatitis market size has grown strongly in recent years. It will grow from $6.43 billion in 2023 to $6.79 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%.

The growth observed in the historical period can be attributed to factors such as the increased prevalence of the condition, advancements in diagnostic techniques, the availability of diverse treatment options, and regulatory approvals for these treatments.

The dermatitis market size is expected to see strong growth in the next few years. It will grow to $8.37 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The anticipated growth in the forecast period can be attributed to increasing patient awareness and the influence of environmental factors. Notable trends expected during this forecast period include a focus on research and development, the integration of telemedicine and digital health solutions, the development of biologics and targeted therapies, and an emphasis on personalized medicine approaches.

The primary categories of drugs used to manage dermatitis include corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, and interleukin inhibitors. Corticosteroids are a group of steroid hormones produced by the adrenal cortex in vertebrates, and synthetic versions of these hormones are also used. These drugs can be administered through different routes, such as topical (applied to the skin), oral (taken by mouth), and injectable (administered by injection), and they find applications in the treatment of conditions like cancer, blood disorders, chronic diseases, and infectious diseases. Dermatitis treatments are available through various channels, including hospitals, retail pharmacies, drug stores, as well as online or mail-order pharmacies.

The dermatitis market research report is one of a series of new reports that provides dermatitis market statistics, including dermatitis industry global market size, regional shares, competitors with a dermatitis market share, detailed dermatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatitis industry. This dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth of the dermatitis market is primarily attributed to the increasing global prevalence of the disease. The prevalence of dermatitis is estimated to be around 15-20% in children and 1-3% in adults. The rising incidence of food allergies is contributing to the prevalence of dermatitis, leading to a higher demand for medications to treat this condition. For instance, in October 2022, the Global Atopic Dermatitis Atlas (GADA), published by the International Eczema Council (IEC), reported approximately 223 million individuals affected by atopic dermatitis in 2022, with around 43 million in the age group of 1 to 4 years.

The rise in the global geriatric population is expected to drive the growth of the dermatitis market. Certain types of dermatitis, such as seborrheic and contact dermatitis, are more common in the elderly due to age-related changes in the skin, making them more susceptible to skin irritants and allergens. This creates an opportunity for the dermatitis market to develop specialized solutions to address the dermatological concerns of the aging population. For example, according to the World Health Organization in October 2022, the global population of individuals aged 60 years and older is projected to increase to 1.4 billion by 2022, compared to 1 billion in 2020. By 2030, one out of every six people in the world will be aged 60 years or older.

Strict government regulations pose a challenge for the dermatitis market. Clinical trials for Atopic Dermatitis (eczema), which often occurs at a very early age, require specific testing on children due to differences in drug effects between adults and children. Regulatory requirements set by organizations like the FDA necessitate additional safeguards for children participating in clinical trials. This regulatory framework is in compliance with the Children’s Health Act of 2000, which mandates enhanced protection for children in clinical investigations.

The dermatitis market has seen a trend of increasing mergers and acquisitions (M&As), aimed at business expansion and increased market visibility. Vendors in the industry are focusing on collaborations and partnerships to enhance their portfolios and market presence. M&As are strategic moves to reduce competition and increase business scalability. For instance, in March 2022, Pfizer Inc. acquired Arena Pharmaceuticals, Inc., a clinical-stage company developing treatments for dermatology diseases, including atopic dermatitis (AD). This acquisition strengthens Pfizer's portfolio of therapeutic candidates in fields like gastroenterology, dermatology, and cardiology.

Major companies in the dermatitis market are introducing innovative, clean-label, steroid-free products like ARCTIVA to gain a competitive edge and enhance their product offerings. ARCTIVA is a range of steroid-free skincare products designed to treat skin conditions such as eczema and psoriasis, featuring advanced Hydrosurf Glycolipid Technology. In April 2023, Arctiva Wellness, LLC introduced ARCTIVA, which combines scientific research with natural, cruelty-free ingredients and clinically validated, FDA-approved active components to deliver proven results. It is the exclusive product line featuring the revolutionary Hydrosurf Glycolipid Technology, originally discovered in Antarctica.

Major companies operating in the dermatitis market include LEO Pharma AS, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer AG, Encore Dermatology Inc., Meda Pharmaceuticals Inc., Allergan PLC, Bristol-Myers Squibb Co., Anacor Pharmaceutical Inc., Astellas Pharma Inc., Mylan N.V., Valeant Pharmaceutical Inc., Galderma SA, Dow Inc., Connetics Corporation, Fujisawa Pharmaceutical Company Ltd., AbbVie Inc., F. Hoffmann-La Roche Ltd., Valeant Pharmaceuticals International Inc.,, GlaxoSmithKline PLC, Medimmune Inc., Bausch Health Co. Inc., Nestlé Skin Health India Pvt. Ltd., Aqua Pharmaceuticals Pvt. Ltd., C.H. Boehringer Sohn AG & Co. KG, Biofrontera AG, Zydus Lifesciences Limited

North America was the largest region in the dermatitis market in 2023. Middle East is expected to be the fastest-growing region in the dermatitis market report during the forecast period. The regions covered in the dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The dermatitis market consists of sales of Stasis dermatitis, atopic dermatitis, and irritant contact dermatitis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.